6-({4,5-dihydroxy-2-methyl-6-[(3,4,5,6-tetrahydroxyoxan-2-yl)methoxy]oxan-3-yl}oxy)-3,4,5-trihydroxyoxane-2-carboxylic acid

Metabolite details

Identifier

CNYXILZYNFTSPQ-UHFFFAOYSA-N

InChI Key

CNYXILZYNFTSPQ-UHFFFAOYSA-N

IUPAC name

6-[4,5-dihydroxy-2-methyl-6-[(3,4,5,6-tetrahydroxyoxan-2-yl)methoxy]oxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid

Preferred name

6-({4,5-dihydroxy-2-methyl-6-[(3,4,5,6-tetrahydroxyoxan-2-yl)methoxy]oxan-3-yl}oxy)-3,4,5-trihydroxyoxane-2-carboxylic acid

INN name

—

Synonym

—

ChEBI

CHEBI:185103

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Bioaccumulation of therapeutic drugs by human gut bacteria: cross-feeding metabolite analysis (FIA-MS) (E.rectale;S.salivarius assays)
• Diallyl disulfide (DADS) ameliorates intestinal Candida albicans infection by modulating the gut microbiota and metabolites and providing intestinal protection in mice
• Effects of Radiofrequency Field from 5G Communications on fecal microbiome and metabolome profiles in mice
• Interaction between Cervical Microbiota and Host Gene Regulation in Caesarean Section Scar Diverticulum
• Alterations in the gut microbiota and metabolomics of seafarers after a six-month sea voyage

Observed in differential profiles

• G4_Eubacterium_rectale_DMSO_30_vs_G3_Eubacterium_rectale_Duloxetine_47
• G1_PBS_vs_G2_DSS
• Sham_vs_Radiofrequency
• Control_vs_CSD
• Control_0d_vs_Treatment_180d
• Control_0d_vs_Treatment_180d